Review Article
Role of Rifaximin in Spontaneous Bacterial Peritonitis Prevention
Abstract
Cirrhosis affects millions of people around the world and is associated with increased morbidity and mortality. Spontaneous bacterial peritonitis (SBP) is a common complication of liver disease with cirrhosis and accounts for up to 30% of infections in patients with cirrhosis. Patients with a history of SBP and those deemed to be at high risk often are prescribed antibiotics to reduce the incidence of SBP. Fluoroquinolones and sulfamethoxazole-trimethoprim are commonly used antibiotics for long-term prevention for these specified populations; however, these antibiotics are associated with several adverse effects and interactions that may be harmful to patients. In addition, resistance development may decrease the efficacy of SBP treatment and prophylaxis. Given these limitations, rifaximin, a nonabsorbable, broad-spectrum antibiotic that is used for hepatic encephalopathy, may serve as a prophylactic alternative to conventional therapy. This review discusses guideline-recommended therapy and the evidence for using rifaximin for SBP prophylaxis.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med 2016;375:767-777.
2. Starr SP, Raines D. Cirrhosis: diagnosis, management, and prevention. Am Fam Physician 2011;84:1353-1359.
3. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2011;61:297-310.
4. Koulaouzidis A, Bhat S, Saeed AA. Spontaneous bacterial peritonitis. World J Gastroenterol 2009;15:1042-1049.
5. Bernardi M. Spontaneous bacterial peritonitis: from pathophysiology to prevention. Intern Emerg Med 2010;5(suppl 1):S37-S44.
6. Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis-bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther 2015;41:1116-1131.
7. Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol 2016;8:307-321.
8. Lutz P, Nischalke HD, Strassburg CP, et al. Spontaneous bacterial peritonitis: the clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol 2015;7:304-314.
9. Kashani A, Landaverde C, Medici V, et al. Fluid retention in cirrhosis: pathophysiology and management. QJM 2008;101:71-85.
10. Runyon BA. Practice guideline. Management of adult patients with ascites due to cirrhosis: update 2012. https://www.aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Published 2012. Accessed September 4, 2018.
11. Tandon P, Kumar D, Seo YS, et al. The 22/11 risk prediction model: a validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Am J Gastroenterol 2013;108: 1473-1479.
12. Alexopoulou A, Vasilieva L, Agiasotelli D, et al. Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia. World J Gastroenterol 2016;22:4049-4056.
13. Shi L, Wu D, Wei L, et al. Nosocomial and community-acquired spontaneous bacterial peritonitis in patients with liver cirrhosis in China: comparative microbiology and therapeutic implications. Sci Rep 2017;7:46025.
14. Li YT, Yu CB, Huang JR, et al. Pathogen profile and drug resistance analysis of spontaneous peritonitis in cirrhotic patients. World J Gastroenterol 2015;21:10409-10417.
15. Fernández J, Tandon P, Mensa J, et al. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology 2016;63:2019-2031.
16. Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012;56(suppl 1):S1-S12.
17. Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014;60:1310-1324.
18. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
19. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55(suppl 6): vi1-vi12.
20. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-824.
21. Ginés P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12( 4 Part 1 ):716-724.
22. Soriano G, Guarner C, Teixidó M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-481.
23. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997;25:532-536.
24. Grangé JD, Roulot D, Pelletier G, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998;29:430-436.
25. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008;48:774-779.
26. Singh N, Gayowski T, Victor LY, et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995;122:595-598.
27. Lontos S, Shelton E, Angus PW, et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis 2014;15:260-267.
28. Alvarez RF, Mattos AA, Correa EB, et al. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arq Gastroenterol 2005;42:256-262.
29. Saab S, Hernandez JC, Chi AC, et al. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009;104:993-1002.
30. Bactrim (sulfamethoxazole and trimethoprim)
31. Cipro (Ciprofloxacin)
32. Lexi-Drugs. Lexicomp. http://online.lexi.com. Accessed January 10, 2016.
33. US Food and Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm. Published July 26, 2016. Accessed May 25, 2017.
34. Wieczorkiewicz JT, Lopansri BK, Cheknis A, et al. Fluoroquinolone and macrolide exposure predict Clostridium difficile infection with the highly fluoroquinolone- and macrolide-resistant epidemic C. difficile strain BI/NAP1/027. Antimicrob Agents Chemother 2015;60:418-423.
35. Leffler DA, Lamont JT, et al. Clostridium difficile infection. N Engl J Med 2015;372:1539-1548.
36. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-834.
37. Lofgren ET, Cole SR, Weber DJ, et al. Hospital-acquired Clostridium difficile infections estimating all-cause mortality and length of stay. Epidemiology 2014;25:570-575.
38. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039-2046.
39. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010;105:106-113.
40. de Mattos AA, Costabeber AM, Lionç LC, et al. Multi-resistant bacteria in spontaneous bacterial peritonitis: a new step in management? World J Gastroenterol 2014;20:14079-14086.
41. Garcia-Tsao G, Lim J. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802-1829.
42. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-148.
43. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Current Opin Gastroenterol 2010;26:17-25.
44. Calanni F, Renzulli C, Barbanti M, et al. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo) 2014;67:667-670.
45. Shayto RH, Abou Mrad RA, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016;22:6638-6651.
46. Xifaxan (rifaximin)
47. DuPont HL. Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases. Mayo Clin Proc 2015;90:1116-1124.
48. Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-2206.
49. Iadevaia MD, Prete AD, Cesaro C, et al. Rifaximin in the treatment of hepatic encephalopathy. Hep Med 2011;3:109-117.
50. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004;10:1009-1011.
51. Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014;12:1390-1397.e2.
52. Ramos JM, Vidal I, Bellot P, et al. Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis. Gut 2016;65:182-183.
53. Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013;28: 450-455.
54. Hanouneh MA, Hanouneh IA, Hashash JG, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012;46:709-715.
55. Lutz P, Parcina M, Bekeredjian-Ding I, et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One 2014;9 : e93909.
56. Shamseya MM, Madkour MA. Rifaximin: a reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis. Alexandria J Med 2016;52:219-226.
57. Elfert A, Abo Ali L, Soliman S, et al. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2016;28:1450-1454.
58. Assem M, Elsabaawy M, Abdelrashed M, et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatology Int 2016;10:377-385.
59. Mostafa T, Badra G, Abdallah M. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients. Turk J Gastroenterol 2015;26:163-169.
